Inventiva S.A

General Information
Business:

(NOTE: A public offering: Our ordinary shares are listed on Euronext Paris under the symbol “IVA.” On July 8, 2020, the closing price of our ordinary shares on Euronext Paris was €14.28 per ordinary share, equivalent to a price of $16.17 per ADS, assuming an exchange rate of €0.8833 per U.S. dollar, based on the exchange rate on July 8, 2020. .)

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases with significant unmet medical need. We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 88
Founded: 2011
Contact Information
Address 50 rue de Dijon 21121 Daix France
Phone Number +33 3 80 44 75 00
Web Address http://www.inventivapharma.com
View Prospectus: Inventiva S.A
Financial Information
Market Cap $549.65mil
Revenues $11.2 mil (last 12 months)
Net Income $-30.6 mil (last 12 months)
IPO Profile
Symbol IVA
Exchange NASDAQ
Shares (millions): 7.5
Price range $14.40 - $14.40
Est. $ Volume $107.7 mil
Manager / Joint Managers Jefferies/ Stifel/ Guggenheim Securities
CO-Managers H.C. Wainwright/ Roth Capital Partners/ KBC Securities
Expected To Trade: 7/10/2020
Status:
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change